⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110957 | 0.94 | — | — | |
| SCHEMBL510435 | 0.74 | CHRM2 (0.36) | — | |
| SCHEMBL11418167 | 0.72 | — | — | |
| SCHEMBL7343467 | 0.72 | CHRM2 (0.30) | — | |
| SCHEMBL2786900 | 0.72 | — | — | |
| SCHEMBL946850 | 0.72 | — | — | |
| SCHEMBL7345580 | 0.69 | — | — | |
| SCHEMBL4630502 | 0.69 | OPRK1 (0.33) | — | |
| SCHEMBL1302866 | 0.68 | BCHE (0.38) | — | |
| SCHEMBL1712855 | 0.68 | BCHE (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | claimed |
| US-20100029605-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-02-04 | — | — | US | claimed |
| US-20090131437-A1 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | CORIUM INTERNATIONAL, INC. (US) | 2009-05-21 | — | — | US | claimed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | claimed |
| EP-1838700-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | claimed |
| WO-2006072589-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-07-13 | — | — | WO | claimed |
| US-8710054-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-04-29 | — | — | US | disclosed |
| EP-2170906-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-04-03 | — | — | EP | disclosed |
| US-20130079330-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2013-03-28 | — | — | US | disclosed |
| US-8338592-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8202876-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2012-06-19 | — | — | US | disclosed |
| EP-2057146-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| WO-2009001089-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008042639-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| EP-1838700-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | Novartis AG (CH) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072589-A2 | DISUBSTITUTED UREAS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-07-13 | — | — | WO | disclosed |